Ascorethat canaccurately determine the risk of major bleeding during anticoagulant therapy mayhelptomakedecisions on anticoagulant use.RIETEi sa no ngoing registryo fc onsecutive patientsw ith acute venous thromboembolism( VTE). We composed ascoretopredict the riskfor major bleeding within three monthso fa nticoagulant therapy.Of1 9,274 patients enrolled, 13,057 (67%) were randomlyassigned to the derivation sample,6,572 to the validationsample. In the derivation sample 314 (2.4%)p atientsb led( fatal bleeding, 105). On multivariate analysis,age >75years, recent bleeding, cancer,creatininelevels >1.2mg/dl, anemia, or pulmonaryembolism at baseline were independentlyassociated with an increasedriskfor major bleeding.A score was composed assigning2points to recent bleeding,
Introduction
Bleeding is the major side effect of anticoagulant therapyinpatients with venous thromboembolism (VTE) (1) (2) (3) (4) .Reliableinformation on the factorsdetermining the risk for major bleeding mayfacilitate betteruse of therapy by improving selection of patients in whom its benefitwill likelyoutweigh the risk, and by identifying thosewho maybenefit from careful management. In addition, earlydetection and prompt treatment of major bleeding with supportive measures might reduce mortality.
So fartwo prospectively validatedprediction ruleshavebeen publishedfor assessing individual risk of major bleeding during the first three months, both with several limitations in clinical practice. Over 50%ofpatients in one studyreceivedanticoagulant therapyt op revent arterial thromboembolism (i.e.c ardiac valver eplacement,a trialfibrillation) (5) . Theo thers tudy was constructed and validatedw ith VTEp atients participating in a randomized clinical trial ( 6) . Since patients with contraindications for anticoagulant therapywere notincludedinthat trial, their findings mayhardly be translated to real world.
TheR IETE Registryi sa no ngoing, international (Spain, France, Italy, Israel,Argentina), multicenter,prospectiveregistry of consecutivepatients presenting with symptomatic acuteVTE confirmed by objective tests (7) (8) (9) (10) (11) . In this analysis, the inci-denceo fm ajor bleeding within three monthso fa nticoagulant therapyw as evaluatedf irst. Then, ab leeding risk prediction scorebased on variablesthat canbeobtained before the institution of anticoagulant therapyw as composed. The aimo ft he study wastoproposearisk scorebased on VTEpatients included in alarge registryreflecting real-lifecurrent clinicalpractice.
Patientsand methods

Inclusioncriteria
Consecutivepatients with symptomatic,acutedeep vein thrombosis (DVT) or pulmonary embolism (PE), confirmed by objective tests (contrastvenographyorultrasonographyfor suspected DVT; pulmonaryangiography, lung scintigraphy, or helicalcomputed tomography[CT] scan forsuspected PE), were enrolledin RIETE. Patients were excluded if theywere currentlyparticipating in atherapeutic clinicaltrial with ab lind therapyorifthey will not be availablef or at hree-month follow-up. All patients provided oralc onsent to their participation in the registry,a ccording to the requirementsofthe ethics committee within each hospital.
The attending physicians ensuret hat eligible patients were consecutively enrolled. Data are recorded on to ac omputerbasedc aser eport forma te ach participating hospitala nd submitted to acentralized coordinating center throughasecurewebsite. Patient identitiesr emainc onfidential because theya re identifiedbyaunique number assigned by the studycoordinating center,w hich is responsible for all data management. Data quality is regularly monitored and documented electronically to detect inconsistenciesorerrors, whichare resolved by the local coordinators. Data quality is also monitoredbyperiodic visits to participating hospitals, by contract research organizations,who compare the medicalrecords with the data in the web. Afull data audit is performed at periodic intervals. VTE, venous thromboembolism;NSAIDs, nonsteroidal anti-inflammatory drugs; PE, pulmonary embolism; LMWH, low-molecular-weightheparin; UFH, unfractionatedheparin; IU,internationalunits; AVK, anti-vitaminKdrugs; CI,confidence intervals; NS, non significant.
Study design
The major outcome for thisstudy wasthe ability to distinguish betweenpatients at low, mild or high risk of experiencing major bleeding during the first 90 days of therapy. Bleeding complications were classified as major if theywere overtand requireda transfusion of twou nits of blood or more,o rw ere retroperitoneal,spinal or intracranial, or when theywere fatal.
Study variables and definitions
The following parameters are recorded:patient'sbaseline characteristics (gender,age, body weight);clinical status including anycoexisting or underlying conditions suchaschronic heart or lung disease, or renal insufficiency; recent( <15d aysp rior to VTE) major bleeding;risk factorsfor VTE (cancer,immobilization, surgery); useofantiplatelets, corticosteroids or nonsteroidal anti-inflammatoryd rugs; biologicald ata( serumc reatinine levels, plateletcount and anemia); the type and dose of treatment received upon VTEdiagnosis; and the outcome during the first three monthso ft herapy. Immobilized patients are defineda s non-surgicalpatients whohad been immobilized (i.e. totalbed restwith bathroom privileges) for ≥4daysinthe two-month period prior to VTE diagnosis. Surgicalpatients are definedasthose whohad undergone an operation in the twomonths prior to VTE. Anemia wasdefinedasanhaemoglobin content <13g/dl for men and <12 g/dl forwomen.
Follow-up
Patients were managedaccording to the clinical practiceofeach participating hospitaland were notsubjecttoany predetermined intervention. Afterh ospital discharge, allp atients were followed-up for threemonths. During each visit, anysigns or symptoms suggesting eitherDVT or PE recurrences or bleeding complications were noted. Each episode of clinically suspected recurrentD VT or PE wasdocumented by repeat ultrasonography, venography, lung scanning, helical-CTscan or pulmonary angiography.
Statisticalanalysis
Acommercial softwarepackage(SPSS 13.5,SPSS Inc.,Chicago, IL, USA) wasusedtocalculateodds ratios and corresponding 95% confidenceintervals (CI), and ap-value<0.05 wasconsideredtobestatistically significant. The predictivevalue of selected variablesfor major bleeding during the first three months of therapywas evaluatedbylogistic regression. Candidate variablesavailableatentrywere based on publishedliterature or in expertopinion. Multivariate logistic analysis wascarried outto identify independent predictorsofbleeding after adjustment for interactionsb etween characteristics, in ordert op redict any bleeding event,a nd the corresponding Kaplan-Meiers urvival curveswere constructed.Significance levelofp<0.10 wasconsideredtoinclude and excludevariablesinthe final multivariate model. Thelong-term treatment receivedbythe patients wasnot included in the multivariate models as it hasb een performed using variablesa vailablea te ntry. Va riablesa fter entry into the registry were notincludedfor the predictive bleeding score. We composedar isk scoring systemi nw hich we assigned points to each risk factor according to the regression coefficients β,rounding to the nearest integer.Arisk score wasassignedto each patient by adding up the points for each risk factor present. Then, we selected the best cut-off scorediscriminating between low-,intermediate-and high-risk patients for major bleeding.We performed across-validation procedure by selecting the sample randomlyinto 67% of patients for the derivation sample and 33% forthe internal validation sample.The likelihood ratio for each stratum wasc alculated by dividing the percentage of patients with major bleeding in thatsubgroup by the percentage without bleeding in thatsubgroup.
Results
As of June 2007, 19,274 patients withacuteVTE were enrolled at 123participating hospitals. Of them, 13,057 (67%) were randomlyassignedtothe derivation sample,6,572 to the validation sample.Both samples had similar clinicalcharacteristics at baseline, treatment details and three-month outcome (Table 1) .
Derivation patient group
During thestudy period 314patients (2.4%) had major bleeding (fatal in 105). Themost frequent sites of bleeding were the gastrointestinal tract (34%), muscular(15%),genitourinary (12%), and brain(11%).Inthe univariate analysis age >75 years,body weight <70kg, cancer, recent immobility,recent bleeding,use of antiplatelets or corticosteroids,creatinine levels >1.2 mg/dl,abnormal prothrombin time, thrombocytopenia, anemia, and PE diagnosis at baseline were associated with an increased risk for major bleeding (Table 2 ).M ultivariate analysis confirmed that onlyage >75years,recent bleeding,cancer,abnormal creatinine levels, anemia,and PE diagnosis at baseline were independently associatedwith an increased risk for major bleeding (Table 3) . Patients with recent bleeding were assigned2points,those with creatinine levels >1.2 mg/dl or anemia 1.5 points each, age >75 years,cancer or PE diagnosis at baseline 1point each.
Clinical score
When these six independent variableswere added into the derivation patient group, patients with arisk scoreof0points had a 0.3% (95% CI: 0.1-0.6) incidenceofmajor bleeding (9 in 2,654 patients) and theyw ere identifiedaslow-risk,compared to the 2.6% (95% CI: 2.3-2.9) incidencein9,645 (75%)patients at intermediate-risk (score1-4), and the 7.3% (95% CI: 5.6-9.3) in 758 (5.8%)patients at high-risk, as shown in Table4a. Theincidenceofmajor bleeding in the three groups were statistically different (p <0.001) as shown in Table4band in Figure 1 . The likelihood ratio test was0.14 (95% CI: 0.07-0.27) for patients at low 
Discussion
Our data, obtained from alarge prospectiveseries of consecutive patients in the RIETE registry,reveal thatwith six clinical variablesdocumented at entry, it is possible to identifyVTE patients at low, intermediate, or high risk formajor bleeding during the first three monthsoftherapy. Major bleeding occurred in 2.4%of patients, and in one in everythreecases major bleeding wasfatal. Thus,its clinical impact is considerable. Thefrequencyofmajor bleeding in our studywas similar to thatreported in several randomized clinical trials (2, (12) (13) (14) , and this is important because, unliket he careful patient selection that characterizes clinical trials, our patient population reflects routine, unmonitoredmedical practiceinvolving abroad spectrum of patients with VTE. We found elderlypatients, or thosewith co-morbid diseases such as cancer,recentb leeding, anemia or renal insufficiency,tobemore likelyt oh avem ajorb leedingt hant hosew ithout these features. Such dataare not usuallyavailable fromthe published randomized clinical trials of anticoagulanttherapy, because these "high-risk" patients are typicallyexcludedfromsuchstudies. However, recentreports have demonstrated their influence on ther isk forb leeding (15) (16) (17) (18) .The Outpatient BleedingR isk Indexi ncludedf our independent risk factors: age ≥65 years, history of gastrointestinal bleeding, history of stroke, andone or more of four specific comorbidc onditions:r ecentm yocardial infarction,h aematocrit <30%, creatinine levels >1.5mg/dl,ordiabetes mellitus(5).However,over 50% of patients receivedw arfarin to preventarterial thromboembolism insteadofVTE. The Dutch score wasconstructed andvalidated with VTEpatients participatinginaclinical trial, andincluded three variables:age,genderand cancer (6) . However, patients with recentg astrointestinal bleeding, stroke, or contraindications for anticoagulantt herapyw ere ineligible fort he study.Other clinical scores have been developed, butnot in patients withVTE (10, 19) . The present study has potential limitations that should be addressed. First,the study is limited by the lack of information on internationalnormalised ratio (INR) control and details relating to type of vitamin Kantagonists (VKA) used. Second,the risk of bleeding is also probablymodified by characteristics thatchange during the course of therapy, sucha st he use of concomitant medications,orthe presenceofintercurrent illnesses. Third,we composedarisk prediction scorebased on registrydata, which wasusedfor both the derivation and the validation patient group, although not the same patients, and this methodology reducesthe external validity of the score. Finally, VTE patients for whom a follow-up of threemonths would not be feasible arenot included in RIETE. These mayhavebeen the sickest patients with an even higher risk of bleeding.
In summary, we composedasimple risk score based on variablesavailableatentry, thatcan reliablyidentify VTE patients at low, mild or high risk for major bleeding.This information may be useful for clinicians weighingthe risks and benefits of prescribing long-termanticoagulant therapy.
